A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 1058-1066

  Kunishima, Tomoyuki ^a   Musha, Haruki ^a   Eto, Fumihiko ^a   Iwasaki, Tatsuya ^a   Nagashima, Junzo ^a   Masui, Yoshihiro ^a   So, Takehiko ^a   Nakamura, Toshika ^a   Oohama, Nagatoshi ^a   Murayama, Masahiro ^a  

^a ST MARIANNA UNIVERSITY   (Japan)

Author keywords

Cilostazol; Percutaneous transluminal coronary angioplasty; Restenosis; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 9844255579     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80058-6     Document Type: Article

References (27)

1. Califf RM, Willerson JT. Thrombosis in cardiovascular disorders. In: Fuster V, ed. Percutaneous Transluminal Coronary Angioplasty: Prevention of Occlusion and Restenosis. Philadelphia: WB Saunders; 1992:389-408.
2. Sanders M. Angiographic changes 30 minutes following percutaneous coronary angioplasty. Angiology. 1985;36:419-424.
3. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angioplasty: An overview. J Am Coll Cardiol. 1991;17 (Suppl B):2B-13B.
4. Haude M, Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. J Am Coll Cardiol. 1993;21:26-34.
5. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronarystent placement and balloon angioplasty in the treatment of coronary artery disease. NEJM. 1994;331:496-501.
6. Serruys PW, de Jaegere P, Keimeneij F, et al, for the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. NEJM. 1994;331:489-495.
7. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91: 1676-1688.
8. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
9. Nishi T, Tabusa F, Tanaka T, et al. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl 1-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull (Tokyo). 1983; 31:1151-1157.
10. Tanaka T, Ishikawa T, Hagiware M, et al. Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
11. Pan X, Arauz E, Krzanowski JJ, et al. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDEIII and PDEIV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48:827-835.
12. Brown BG, Bolson E, Frimer M, Dodge HT. Quantitative coronary angiography. Circulation. 1977;55:329-337.
13. Bourassa MG, Alderman EL, Bertrand M, et al. Report of joint ISFC/WHO task force on coronary angioplasty. Circulation. 1988;78:780-789.
14. Ryan T, Loop FD, Faxon DP, et al. Guidelines for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1988;12:529-545.
15. Gruentzig AR, Myler RK, Hanna ES, Marco I. Coronary transluminal angioplasty. Circulation. 1977;55 and 56(Suppl III):III-84. Abstract.
16. Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76: 450-457.
17. Jain SP, Jain A, Collins TJ, et al. Predictors of restenosis: A morphometric and quantitative evaluation by intravascular ultrasound. Am Heart J. 1994;128: 664-673.
18. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993;362:801-809.
19. Albiero R, Hall P, Itch A, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Circulation. 1997;95: 1145-1156.
20. 2 and prostacyclin. Stroke. 1992;23:1400-1403.
21. Panak E, Maffrand JP, Picard-Fraire C, et al. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis. 1983;13 (Suppl I): 1-54.
22. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
23. Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. NEJM. 1988;319:733-740.
24. Okamoto S, Inden M, Setsuda M, et al. Effect of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1439-1444.
25. Wu J, Dent P, Jelinek T, et al. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 1993;262:1065-1069.
26. Cook SJ, McCormick F. Inhibition by cAMP of ras-dependent activation of raf. Science. 1993;262:1069-1072.
27. Graves LM, Bornfeldt KE, Raines EW, et al. Protein kinase A antagonizes plateletderived growth factor-induced signaling mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA. 1993;90:10300-10304.